NEONC Biotech Secures $50M Investment for Brain Cancer Trials & MENA Expansion | NewsOut

Jul 30, 2025

Investors and biotech enthusiasts, NEONC Technologies Holdings has announced a $50 million strategic partnership with Quasar Investment to accelerate its groundbreaking clinical trials for brain and CNS cancers.

A multiphase 2 clinical-stage biotech company, NEONC is advancing transformative treatments for brain and central nervous system malignancies. This equity investment—approved unanimously by the board—will fuel expansion into the UAE, Middle East, and North Africa, marking a bold step in the company’s international growth and research pipeline.

Get the latest update from the floor of the New York Stock Exchange.

🏷️ Tags:
#NEONC
#BiotechNews
#BrainCancerTreatment
#CNSCancer
#ClinicalTrials
#BiotechInvestment
#QuasarInvestment
#MENAExpansion
#UAEHealthcare
#CancerResearch
#LifeSciences
#BiotechStocks
#StrategicPartnership
#NewYorkStockExchange